Sarclisa (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma

Sanofi

8 July 2020 - First and only anti-CD38 antibody in combination with pomalidomide and dexamethasone to be approved in Canada.

Sanofi Canada is pleased to announce that Health Canada has approved Sarclisa in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

The approval of Sarclisa by Health Canada was based on the ICARIA-MM study.

Read Sanofi press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada